google.com, pub-3052420416507494, DIRECT, f08c47fec0942fa0

Aditya Birla Sun Life Mutual Fund offers the Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth, a sectoral-pharmacy mutual fund scheme. This fund was launched on June 20, 2019, and has been in operation for five and a half years. As of September 30, 2024, the fund has ₹854 crores in assets under management (AUM) and is classified as a medium-sized fund in its category. The most recent Net Asset Value (NAV) as of December 24, 2024, is ₹34.05. With an expense ratio of 0.93%, it is higher than that of most similar sectoral-pharma funds.

The Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth has seen direct growth returns of 36.67% over the past year and has provided average annual returns of 25.14% since its inception. Investments in this fund double every three years.

Overall, the performance of the Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth scheme is comparable to other similar funds in the 

Every three years, the amount invested in the fund doubles.

Birla Aditya Sun Life Pharma & Healthcare Fund Direct-Growth scheme’s performance is comparable to that of the majority of funds in its category. It performs below average when it comes to managing losses in a declining market.

The healthcare, services, and chemical industries account for the majority of the fund’s investments. Compared to other funds in the category, it has taken on less exposure in the healthcare and services sectors.

By investing in equities and equity-linked instruments of Indian companies in the pharmaceutical, healthcare, and related industries, the program aims to generate long-term financial appreciation.

A sectoral mutual fund with an emphasis on the pharmaceutical and healthcare industries is the Aditya Birla Sun Life (ABSL) Health and Pharma Fund. This is a summary of the fund:Important attributes:

Sectoral Focus: Invests mostly in businesses in the pharmaceutical, healthcare, and related sectors.

High-Risk, High-Return: This sectoral fund is focused on a single industry and is subject to volatility based on the success of that industry.

Growth Potential: Because of things like evolving healthcare needs, innovation, and demographic shifts, the pharmaceutical and healthcare industries typically have room to develop over the long run.

Asset Under Management

Tax Implications on Aditya Birla Sun Life Pharma & Healthcare Fund Regular-Growth

1. If units are redeemed within a year after investment, gains are subject to 15% short-term capital gain tax, or STCG. 
2. Gains from units that are redeemed after a year of investment are exempt from taxes up to Rs. 1 lakh within a fiscal year. 
3. The Long-term Capital Gain Tax, or LTCG, levies a 10% tax on gains above Rs. 1 lakh. 
4. In terms of dividend distribution tax, the investor’s income will be increased by the dividend income from this fund, which will then be taxed in accordance with their individual tax slab. 
5. Additionally, the fund company must deduct a 10% TDS from dividend income over Rs 5,000 in a fiscal year.

6. Minimum Investment: A minimum of Rs 1000 must be invested, and an additional Rs 1000 must be invested. Rs 100 is the minimum SIP investment.

Return of Investment:

Return on Invest

Things to take Into Account:

ABSL Pharma  and Health
  • Performance: Examine the fund’s past results in relation to its benchmark.
  • Examine the fund’s expense ratio; a lower percentage means that more returns are kept in the fund.
  • Market Conditions: If there are challenges in a particular area, sectoral funds may perform poorly.
  • Diversification: To prevent your portfolio from becoming overly concentrated, reduce your exposure to sectoral funds.

Asset Allocation:

Asset Allocation

Sector wise Allocation:

ABSL Pharma and Healthcare

Returns since Inception

Return on Invest

Note: Please reads all documents before investment in share market related product and get advise from your financial advisor.


Discover more from Financialrelease

Subscribe to get the latest posts sent to your email.

Leave a Reply

Discover more from Financialrelease

Subscribe now to keep reading and get access to the full archive.

Continue reading